1/ I'm all in short on $REPL
They got rejected because the filed study was not adequate and well-controlled.
Their answer was not to produce a new study.
Their answer was to run the same one back.
CRL is comingπ§΅
it's the same antibody, same 5mg. a fifth of it moved from conjugated to free. viscosity fix, marketing story.
plus daylight already ran max drug in the eye. 5mg monthly, 12 doses. +2.5 letters vs eylea q8w's +4.6. that "win" cleared NI by 0.62 letters (β3.88 vs a β4.5 margin), on 50% more injections. that's the ceiling of ur exposure argument. it's already been measured. and it sucked.
20/ Scoreboard: $443.6 million lost since they started. Approved drugs: zero.
This trial misses. Short it.
And if the headline says "positive" anyway, short more. Yuichi Iwaki has done it before.
$MNOV goes to $1-1.5.
19/ They've done this before. March 2007, same CEO.
Headline: "MediciNova Announces Positive Clinical Results."
Third paragraph: the drug missed the main goal the trial was designed to hit.
Their 2007 deck promised the next big MS trial "as early as 08Q2." Kids born that quarter can vote now. Still no big MS trial.